HIPO vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HIPO presents a complex profile characterized by a recent transition to profitability but weak underlying financial health, as evidenced by a Piotroski F-Score of 3/9. While the current price of $28.73 aligns closely with the Graham Number ($29.11), it trades at a significant premium to its growth-based intrinsic value of $15.54. The company shows strong revenue growth and a low P/E relative to the sector, but these are offset by aggressive insider selling and a poor quick ratio. The overall outlook is a cautious neutral, balancing a successful earnings turnaround against deteriorating deterministic health markers.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
HIPO vs JPM: Head-to-Head Comparison
This page compares Hippo Holdings Inc. (HIPO) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.